Sedation and monitoring

Published on 01/04/2015 by admin

Filed under Radiology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 2143 times

Chapter 18 Sedation and monitoring

Sedation

Sedation is the use of a drug or drugs to produce a state of depression of the central nervous system that enables interventional procedures or treatment to be carried out. Over recent years the complexity and number of interventional procedures in radiology departments has increased; often these patients are frail or medically unfit for surgery. Sedation is only part of a ‘package’ of care comprising pre-assessment, properly informed consent, adequate facilities, good techniques and risk avoidance.1

Sedative drugs may be combined with drugs used for pain relief (analgesia). Some drugs, such as benzodiazepines, have purely sedative effects but others, such as opioids, have combined sedative and analgesic effects. Although sedative and analgesic agents are generally safe, catastrophic complications related to their use can occur, often as a result of incorrect drug administration or inadequate patient monitoring.2 The incidence of adverse outcomes is reduced by improved understanding of the pharmacology of drugs used, appropriate monitoring of sedated patients and by recognizing those at increased risk of adverse event.

There is a continuum between the main types of sedation (see Fig. 18.1) defined as:

The joint Royal College of Radiologists/Royal College of Anaesthetists Working Party on Sedation and Anaesthesia in Radiology3 recommended establishment of local guidelines for sedation in radiology. These should include:

DRUGS

As part of a sedation protocol the following may be used:

SEDATIVE DRUGS

For conscious sedation in the radiology department, the water-soluble benzodiazepine midazolam is the drug of choice. Midazolam has superseded diazepam because the latter has active metabolites and longer duration of effect. Midazolam produces:

Midazolam is given i.v. It has a rapid onset of effect, within 1–5 min, and duration of less than 6 h. The sedative dose is 70 µg kg−1 body weight (for average adult approx. 4–5 mg) and the sleep dose is 100–200 µg kg−1 (>7 mg). Typically, 2–2.5 mg is administered i.v. over 30–120 s with further 0.5 mg doses titrated as required. Rarely are total doses of more than 5 mg required. Smaller doses of 1–3 mg must be used in the elderly.

The effects of midazolam can be reversed by the competitive antagonist flumazenil; onset of flumazenil is within 1–3 min with a half-life of 7–15 min. The dose of flumazenil should be titrated every 1–2 min starting with 200 µg and giving a maximum of 1 mg. The clinical effect depends on the dose of flumazenil and sedative given. The half-life of flumazenil is shorter than that of midazolam, therefore, re-sedation effects can occur.

The use of i.v. anaesthetic agents, such as ketamine and propofol, can result in the patient moving quickly from a state of sedation to anaesthesia with concomitant risks. These drugs should only be used by those who have undergone appropriate specialist training.

Sedation of children

Each child should be individually assessed. In most circumstances parents should stay with the child, and with patience and encouragement the need for sedation may be avoided in some cases. Short procedures such as CT can often be achieved in neonates by keeping them awake and then feeding the child and swaddling just prior to the procedure. Often, children over the age of 4–5 years will not need sedation and will cooperate. Local anaesthetic cream, e.g. Ametop, can be applied to a suitable vein prior to insertion of a venous cannula if venous access is required. Oral sedation does not work well in children over the age of 4 and older children who are unable to co-operate will usually require general anaesthetic.

It is important to ensure that all monitoring and resuscitation equipment is suitable for paediatric use. A nurse, experienced in the care of sedated children, should be present throughout. When drugs are given which are likely to result in loss of consciousness, the primary care of the patient should be under the direct supervision of an anaesthetist.

For many years chloral hydrate has been the mainstay for sedation of young children for a variety of procedures. Triclofos is an active metabolite of chloral hydrate which causes less gastric irritation and vomiting. Alimemazine (Vallergan) is a sedating antihistamine, with anticholinergic effects. The recommendations in Table 18.3 are made as being suitable for the majority of patients, in respect of both safety and efficacy. It is recognized that, for certain patients, deviation from these guidelines will be appropriate on clinical or weight grounds (Table 18.3).

Table 18.3 Sedation recommendations made as being suitable for the majority of child patients. These doses are used to acheive deep sedation: a nurse should be present throughout.

Age/weight Sedation Dose
<1 month old Feed only or Triclofos 30 mg kg−1
>1 month old but <5 kg Triclofos 50–70 mg kg−1
5–10 kg Triclofos 100 mg kg−1
>10 kg–4 years Triclofos + Alimemazine 100 mg kg−1 (maximum 2 g) 1 mg kg−1 (maximum 30 mg)
Over 4 years Consider oral sedation as above or general anaesthetic  

Vomiting is not uncommon after oral sedation is given. If the child vomits within 10 min the dose can be repeated. After 10 min a reduced dose of 50–70% of the Triclofos + Alimemazine dose can be repeated. The dose should not be repeated after 20 min as significant absorption may have occurred.

On the night before the procedure or scan parents should be asked to try to keep the child awake for as long as possible. The child should be woken early on the relevant day and no ‘naps’ allowed on the journey to the hospital. This will ensure that the child is already tired prior to administration of the sedation. The sedative medication usually takes about 45 min to take effect.

Children should have nothing to eat or drink prior to sedation as follows:

Complications

Early recognition and treatment of complications is essential to reduce morbidity and mortality from sedation in all patients.

Minor complications include:

Major complications are rare, but include:

Sedation causes a reduction in muscle tone of the oropharynx and at deeper levels of sedation the glottic reflexes may fail. Major complications of sedation are most often due to airway obstruction and respiratory depression. The following patient groups are at high risk:

Monitoring

Monitoring should be used:

The purpose is to observe and assess response of the patient to any psychological or physiological stress imposed by the procedure or sedative agents administered and allow appropriate therapeutic action to be taken.

Equipment

Monitor alarms may be the first signal of an adverse event and should not be silenced. If there is any doubt repeat measurement should be performed.